SCHEMBL3015248

SCHEMBL3015248

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccccc3Br)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.39
MAPT P10636 5/20 0.34
HTR6 P50406 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
C5AR1 P21730 1/20 0.33
RECQL P46063 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
EPHX2 P34913 1/20 0.33
HPGD P15428 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
LTA4H P09960 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007519 0.91 MAPT (0.37) CTSSMAPTHTR6ALDH1A1LMNA
SCHEMBL3016871 0.91 MAPT (0.37) CTSSMAPTALDH1A1LMNARECQL
SCHEMBL3018577 0.89 CTSS (0.40) CTSSMAPTALDH1A1LMNAMEN1
SCHEMBL3015530 0.89 DRD2 (0.40) MAPTDRD2DRD4DRD3ALDH1A1
SCHEMBL3006870 0.88 CTSS (0.41) CTSSMAPTLMNAC5AR1MEN1
SCHEMBL3013002 0.87 SMN1; SMN2 (0.38) MAPTHTR6DRD2DRD4DRD3
SCHEMBL3017061 0.87 CTSS (0.38) CTSSMAPTDRD2DRD4DRD3
SCHEMBL3017583 0.87 CTSS (0.38) CTSSMAPTDRD2DRD4DRD3
SCHEMBL3017613 0.87 DRD2 (0.43) CTSSMAPTDRD2ALDH1A1KMT2A
SCHEMBL3021695 0.87 CTSS (0.40) CTSSMAPTKMT2AEPHX2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885MAPT 18/4885HTR6 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.